Anónimo. Sulfonamide cross-reactivity. The Medical Letter on Drug and Therapeutics Bulletin 2019;61:25 de marzo. [Ref.ID 103061]

Rodríguez-Martín S, Martín-Merino E, Lerma V, Rodríguez-Miguel A, González O. Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. Eur J Clin Pharmacol 2019;75:febrero. [Ref.ID 103013]

Comoretto RI, Rea F, Lucenteforte E, Mugelli A, Trifirò G, Cascini S, Roberto G, Chinellato A, Filippelli A, Corrao G, on behalf of the Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE). Bleeding events attributable to concurrent use of warfarin and other medications in high-risk elderly: meta-analysis and Italian population-based investigation. Eur J Clin Pharmacol 2018;74:1061-70. [Ref.ID 102823]

Muanda FT, Sheehy O, Bérard A. Use of trimethoprim–sulfamethoxazole during pregnancy and risk of spontaneous abortion: a nested case control study. Br J Clin Pharmacol 2018;84:junio. [Ref.ID 102803]

Anónimo. Pneumonies communautaires peu graves chez les enfants. Prescrire 2018;38:518-23. [Ref.ID 102764]

Chan WY, Clark AB, Wilson AM, Loke YK, on behalf of the TIPAC investigators. The effect of co-trimoxazole on serum potassium concentration: safety evaluation of a randomized controlled trial. Br J Clin Pharmacol 2017;83:agosto. [Ref.ID 101544]

Anónimo. Alternatives to fluoroquinolones. Med Lett Drugs Ther 2016;58:75-6. [Ref.ID 100457]

González R, Sevene E, Jagoe G, Slutsker L, Menéndez C. A public health paradox: the women most vulnerable to malaria are the least protected. PLOS Medicine 2016:3 de mayo. [Ref.ID 100350]

Talan DA, Mower WR, Krishnadasan A, Abrahamian FM, Lovecchio F, Karras DJ, Steele MT, Rothman RE, Hoagland R, Moran GJ. Trimethoprim–sulfamethoxazole versus placebo for uncomplicated skin abscess. N Engl J Med 2016;374:3 de marzo. [Ref.ID 100027]

Anónimo. Riesgo de muerte súbita con el uso concomitante de cotrimoxazol y algunos inhibidores del sistema renina-angiotensina. Butlletí de Farmacovigilància de Catalunya 2015;13:1-2. [Ref.ID 99829]

Anónimo. Seguridad de medicamentos: señales y alertas generadas en 2013-2014. Infac: Información Farmacoterapéutica de la Comarca 2015;23:16-26. [Ref.ID 99145]

Wessels MR. Choosing an antibiotic for skin infections. N Engl J Med 2015;372:1164-5. [Ref.ID 98962]

Miller LG, Daum RS, Creech CB, Young D, Downing MD, Eells SJ, Pettibone S, Hoagland RJ, Chambers HF, DMID 07-0051 Team. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. N Engl J Med 2015;372:1093-103. [Ref.ID 98961]

Antoniou T, Hollands S, Macdonald EM, Gomes T, Mamdani MM, Juurlink DN, for the Canadian Drug Safety and Effectiveness Research Network. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. Can Med Assoc J 2015;187:E138-43. [Ref.ID 98766]

Anónimo. Lésions de la muqueuse oesophagienne d'origine médicamenteuse. Prescrire 2014;34:905-10. [Ref.ID 98473]

Bowen AC, Tong SY, Andrews RM, O'Meara IM, McDonald MI, Chatfield MD, Currie BJ, Carapetis JR. Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open-label, randomised, controlled, non-inferiority trial. Lancet 2014;384:2132-40. [Ref.ID 98455]

Anónimo. Drugs for MRSA skin and soft-tissue infections. Med Lett Drugs Ther 2014;56:39-40. [Ref.ID 97620]

Chetchotisakd P, Chierakul W, Chaowagul W, Anunnatsiri S, Phimda K, Mootsikapun P, Chaisuksant S, Pilaikul J, Thinkhamrop B, Phiphitaporn S, Susaengrat W, Toondee Ch, Wongrattanacheewin S, Wuthiekanun V, Chantratita N, Thaipadungpanit J, Day NP, Limmathurotsakul D, Peacock S J. Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet 2014;383:807-14. [Ref.ID 97167]

Fisher DA, Harris PNA. Melioidosis: refining management of a tropical time bomb. Lancet 2014;383:762-4. [Ref.ID 97166]

Anónimo. Drugs for urinary tract infections. JAMA 2014;311:855-6. [Ref.ID 97160]